XM无法为美国居民提供服务。
S
S

Sanofi


市场新闻

French and Benelux stocks-Factors to watch

French and Benelux stocks-Factors to watch Oct 2 (Reuters) - Below are company-related news and stories from France and Benelux which could have an impact on the region's markets or individual stocks. Ageas AGES.BR British holiday group Saga SAGA.L is in talks with Belgium-based insurer Ageas regarding a long-term partnership arrangement for its insurance division, Sky News reported on Tuesday.
A
E
R
S
F
N
U

U.S. Applied Materials, Lam Research, S&P Global

U.S. RESEARCH ROUNDUP-Applied Materials, Lam Research, S&P Global Oct 2 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Applied Materials, Lam Research and S&P Global, on Wednesday. HIGHLIGHTS * Applied Materials Inc AMAT.O : Berenberg cuts target price to $246 from $250 * Bank of Hawaii Corp BOH.N : KBW raises to market perform from underperform * First Citizens BancShares FCNCA.O : KBW cuts target price to $2200 fr
C
N
P
P
S
L
S
A
M
P
R

Sanofi Is Said To Ask For Revised Bids For Its Consumer Health Unit In Coming Days - Bloomberg News

BRIEF-Sanofi Is Said To Ask For Revised Bids For Its Consumer Health Unit In Coming Days - Bloomberg News Oct 1 (Reuters) - SANOFI IS SAID TO ASK FOR REVISED BIDS FOR ITS CONSUMER HEALTH UNIT IN COMING DAYS - BLOOMBERG NEWS Source text: https://tinyurl.com/mvjwrj4f Further company coverage: SASY.PA
S

WHO recommends maternal vaccine and antibody shot to prevent RSV in infants

UPDATE 1-WHO recommends maternal vaccine and antibody shot to prevent RSV in infants Adds comments from WHO press conference in paragraphs 7 to 10 By Kashish Tandon and Bhanvi Satija Oct 1 (Reuters) - The World Health Organization on Tuesday recommended vaccinating pregnant women and administering infants with an antibody to prevent severe respiratory synctial virus (RSV) infection in newborns.
A
G
P
S

WHO recommends maternal shot and antibody therapy to prevent RSV in infants

WHO recommends maternal shot and antibody therapy to prevent RSV in infants Oct 1 (Reuters) - The World Health Organization on Tuesday recommended maternal vaccination and the use of an antibody therapy to prevent respiratory synctial virus (RSV) in infants. The recommendations, to administer both the shot and the antibody or either, come after the WHO's strategic advisory group on immunization met last week.
A
G
P
S

French and Benelux stocks-Factors to watch

French and Benelux stocks-Factors to watch Sept 30 (Reuters) - Below are company-related news and stories from France and Benelux which could have an impact on the region's markets or individual stocks. FRENCH POLITICS France's new Prime Minister Michel Barnier is considering a temporary increase in corporate tax on the country's biggest companies as well as a tax on share buybacks, Le Monde newspaper reported on Sunday.
A
C
E
S
V
V
F
N
U

Regeneron rises as US FDA approves Dupixent for 'smoker's lung'

BUZZ-Regeneron rises as US FDA approves Dupixent for 'smoker's lung' ** Shares of Regeneron Pharmaceuticals REGN.O rise 1.6% to $1,056.92 in early trading ** Co and French partner Sanofi SASY.PA say the U.S. FDA has approved their blockbuster drug, Dupixent, for patients with a chronic lung disease commonly known as "smoker's lung" ** Dupixent is t
R
S

Sanofi-Regeneron's Dupixent wins FDA's nod for 'smoker's lung'

UPDATE 2-Sanofi-Regeneron's Dupixent wins FDA's nod for 'smoker's lung' Adds details on Dupixent in paragraphs 2 and 4, analyst estimates in paragraph 5, trial details in paragraph 8 By Sriparna Roy Sept 27 (Reuters) - The U.S. Food and Drug Administration has approved Sanofi SASY.PA and Regeneron's REGN.O blockbuster drug Dupixent for patients with a chronic lung disease, commonly known as "smoker's lung", the companies said on Friday.
R
S

Dupixent approved in United States as first-ever biologic medicine for patients with COPD

BRIEF-Dupixent approved in United States as first-ever biologic medicine for patients with COPD Sept 27 (Reuters) - Sanofi SA SASY.PA /REGENERON REGN.O : PRESS RELEASE: DUPIXENT APPROVED IN THE US AS THE FIRST-EVER BIOLOGIC MEDICINE FOR PATIENTS WITH COPD PRESS RELEASE: DUPIXENT APPROVED IN THE US AS THE FIRST-EVER BIOLOGIC MEDICINE FOR PATIENTS WI
R
S

US FDA approves Sanofi-Regeneron's Dupixent for 'smoker's lung'

US FDA approves Sanofi-Regeneron's Dupixent for 'smoker's lung' Sept 27 (Reuters) - The U.S. Food and Drug Administration has approved Sanofi SASY.PA and Regeneron's REGN.O blockbuster drug Dupixent for patients with a chronic lung disease commonly known as "smoker's lung", the companies said on Friday. Reporting by Sriparna Roy in Bengaluru; Editi
R
S

What to Watch in the Day Ahead - Friday, September 27

What to Watch in the Day Ahead - Friday, September 27 The Day Ahead is an email and PDF publication that includes the day's major stories and events, analyses and other features. To receive The Day Ahead, Eikon users can register at DAY/US . Thomson One users can register at RT/DAY/US. All times in ET/GMT Federal Reserve Board Governor Michelle Bowman is set to participate in a conversation before the Alabama Bankers Association Bank CEO Meeting in Birmingham, Alabama.
B
R
S

Amgen falls after reporting mixed data on two drugs

BUZZ-Amgen falls after reporting mixed data on two drugs ** Shares of Amgen AMGN.O fall as much as 4.4% to a near two-month low of $316.22 ** Stock is set for its worst day in nearly two months if losses hold ** Late on Tuesday drugmaker said its drugs Uplizna and rocatinlimab, for a rare muscular disorder and a skin disease, respectively, met the
A
R
S

Amgen's muscular disorder drug meets main goal in late-stage study

UPDATE 4-Amgen's muscular disorder drug meets main goal in late-stage study Amgen's Uplizna succeeds in study for muscle-weakening Analysts say data from another experimental drug not 'competitive' Shares fall 2% in extended trading on mixed datasets Adds analyst comments in paragraphs 4, 10 and 11, trial data in paragraph 3, 8 and 9, exec comment in paragraph 6 By Bhanvi Satija and Puyaan Singh Sept 24 (Reuters) - Amgen AMGN.O said on Tuesday that its drug helped improve daily activities includ
A
A
R
S

Deals of the day-Mergers and acquisitions

Deals of the day-Mergers and acquisitions Adds Vitru, Sanofi, London Stock Exchange Group, Warburg Pincus and Macquarie Group; Updates Smartsheet Sept 24 (Reuters) - The following bids, mergers, acquisitions, and disposals were reported by 1930 GMT on Tuesday: * * Brazilian education firm Vitru VTRU3.SA hired banks UBS BB and Itau BBA to find a potential buyer or a firm interested in merging their businesses, newspaper Valor Economico reported, citing sources.
B
C
C
S
U
U
Z
S

Sanofi gets two bids valuing its consumer health unit at about $17 billion, Bloomberg News reports

UPDATE 2-Sanofi gets two bids valuing its consumer health unit at about $17 billion, Bloomberg News reports Adds details from the report in paragraphs 2 and 4, background in paragraphs 8-10 Sept 24 (Reuters) - Sanofi SASY.PA has received two separate bids from private equity firms for its consumer health unit, which could be valued at 15 billion euros ($16.74 billion) or more, Bloomberg News reported on Tuesday.
P
S

Sanofi gets bids for its consumer health unit from two PE firms, Bloomberg News reports

Sanofi gets bids for its consumer health unit from two PE firms, Bloomberg News reports Sept 24 (Reuters) - Sanofi SASY.PA has received two separate bids, which could be worth 15 billion euros ($16.74 billion) or more, for its consumer health unit from private equity firms Clayton Dubilier & Rice and PAI Partners, Bloomberg News reported on Tuesday
S

Sanofi Gets Binding Bids From CD&R, PAI For Consumer Arm That Could Be Valued At €15 Billion Or More - Bloomberg News

BRIEF-Sanofi Gets Binding Bids From CD&R, PAI For Consumer Arm That Could Be Valued At €15 Billion Or More - Bloomberg News Sept 24 (Reuters) - SANOFI GETS BINDING BIDS FROM CD&R, PAI FOR CONSUMER ARM THAT COULD BE VALUED AT €15 BILLION OR MORE - BLOOMBERG NEWS Source text: https://tinyurl.com/yc2h2zfr Further company coverage: SASY.PA
S

Banks And Lenders Line Up More Than 10 Billion Euro Of Debt To Back A Buyout Of Sanofi’s Consumer Health Division - Bloomberg News

BRIEF-Banks And Lenders Line Up More Than 10 Billion Euro Of Debt To Back A Buyout Of Sanofi’s Consumer Health Division - Bloomberg News Sept 24 (Reuters) - BANKS AND LENDERS LINE UP MORE THAN €10 BILLION OF DEBT TO BACK A BUYOUT OF SANOFI SA’S CONSUMER HEALTH DIVISION - BLOOMBERG NEWS Source text: [ https://tinyurl.com/5n8hp4rw ] Further com
S

Sanofi CEO believes company poised for growth from new drugs

UPDATE 1-Sanofi CEO believes company poised for growth from new drugs Adds CEO comments, details on pipeline assets, obesity, paragraphs 1-9 Sanofi has 12 potential blockbuster assets in immunology and vaccines Sanofi has undisclosed obesity pipeline assets, making third-party investments Sanofi still considering spinoff, IPO or sale of Opella consumer healthcare unit By Michael Erman NEW YORK, Sept 23 (Reuters) - Sanofi's SASY.PA chief executive, Paul Hudson, said in an interview on Monday that
S

Sanofi CEO still considering how to split consumer biz, hopes to keep a stake

Sanofi CEO still considering how to split consumer biz, hopes to keep a stake By Michael Erman NEW YORK, Sept 23 (Reuters) - Sanofi SASY.PA Chief Executive Paul Hudson said on Monday that the company has not made a final decision yet on how it plans to split off its Opella consumer healthcare unit, but that it is interested in keeping a stake in the business after the separation is done.
S



商品详情

热门商品

免责声明: XM Group仅提供在线交易平台的执行服务和访问权限,并允许个人查看和/或使用网站或网站所提供的内容,但无意进行任何更改或扩展,也不会更改或扩展其服务和访问权限。所有访问和使用权限,将受下列条款与条例约束:(i) 条款与条例;(ii) 风险提示;以及(iii) 完整免责声明。请注意,网站所提供的所有讯息,仅限一般资讯用途。此外,XM所有在线交易平台的内容并不构成,也不能被用于任何未经授权的金融市场交易邀约和/或邀请。金融市场交易对于您的投资资本含有重大风险。

所有在线交易平台所发布的资料,仅适用于教育/资讯类用途,不包含也不应被视为用于金融、投资税或交易相关咨询和建议,或是交易价格纪录,或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。

本网站上由XM和第三方供应商所提供的所有内容,包括意见、新闻、研究、分析、价格、其他资讯和第三方网站链接,皆保持不变,并作为一般市场评论所提供,而非投资性建议。所有在线交易平台所发布的资料,仅适用于教育/资讯类用途,不包含也不应被视为适用于金融、投资税或交易相关咨询和建议,或是交易价格纪录,或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。请确保您已阅读并完全理解,XM非独立投资研究提示和风险提示相关资讯,更多详情请点击 这里

风险提示: 您的资金存在风险。杠杆商品并不适合所有客户。请详细阅读我们的风险声明